Hyung Kim, MD
Urology · Los Angeles, CANPI 1891792693
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,600 of the $10,088 with a category attached, or 75.3%. EDAP Technomed Inc accounts for 86.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $4,713 and has fallen 98.8% since, to $56 in 2025.
Across 36 payments — averaging $280.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EDAP Technomed Inc$9K
- Intuitive Surgical$650
- Collegium Pharmaceutical, Inc.$207
- AVEO Pharmaceuticals, Inc.$168
- Comsort, Inc$100
- Boston Scientific$82
- plus $128 from 5 others
Across 2 payments — averaging $7681.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15K
What the payments were for
- Consulting fees$7,60075%
- Food & beverage$1,98820%
- Education$5005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EDAP Technomed Inc | 9 | $8,754 |
| Intuitive Surgical | 3 | $650 |
| Collegium Pharmaceutical, Inc. | 14 | $207 |
| AVEO Pharmaceuticals, Inc. | 1 | $168 |
| Comsort, Inc | 1 | $100 |
| Boston Scientific | 3 | $82 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| AstraZeneca | 1 | $31 |
| Johnson & Johnson | 1 | $20 |
| Medtronic | 1 | $19 |
| BD | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$600
- FOTIVDA$168
- KEYTRUDA$100
How this compares
$10,088 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 76 | $39,302 |
| CialisTadalafil | 12 | $3,600 |
| Tadalafil | 12 | $3,129 |
| Tamsulosin Hcl | 201 | $2,123 |
| Oxybutynin Chloride ErOxybutynin Chloride | 48 | $1,089 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,065 |
| Finasteride | 76 | $807 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $467 |
| Dutasteride | 12 | $202 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $106 |
| Sildenafil Citrate | 15 | $97 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.